Patent US6167313A successfully refreshed from Google Patents.
US6167313A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Targeted hysteresis hyperthermia as a method for treating diseased tissue
Assignee: Sirtex Medical Pty Ltd
•
Filing: 1997-05-09
•
Granted: 2000-12-26
•
Expires: 2017-05-09
Abstract
Abstract A method for site specific treatment of diseased tissue in a patient, comprising the steps of: (i) selecting at least a magnetic material which has a magnetic heating efficiency of at least about 4.5×10 -8 J.m./A.g, when magnetic field conditions are equal to or less than about 7.5×10 7 A/s; (ii) delivering the magnetic material to diseased tissue in a patient; and (iii) exposing the magnetic material in the patient to a linear alternating magnetic field with a frequency of greater than about 10 kHz and a field strength such that the product of field strength, frequency and the radius of the exposed region is less than about 7.5×10 7 A/s to generate hysteresis heat in the diseased tissue.
Inventors
- 👤 Bruce Nathaniel Gray
- 👤 Stephen Keith Jones
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 09:34
CPC Classifications
A; A61; A61N; A61N2/00; A61N2/02; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5094; A61K33/00; A61K33/24; A61K33/26; A61K41/00; A61K41/0052; A61N1/00; A61N1/40; A61N1/403; A61N1/406
Claims Analysis
Total Claims: 49
Claim 1
Independent Claim
112 words
A method for site specific treatment of diseased tissue in a patient, comprising the steps of: (i) delivering a magnetic material which has a magnetic heating efficiency of at least about 4.5×10 -8 J.m./A.g. when magnetic field conditions are equal to or less than about 7.5×10 7 A/s to diseased tissue in a patient; and (ii) exposing the magnetic material in the patient to a linear alternating magnetic field with a frequency of greater than about 10 kHz and a field strength such that the product of field strength, frequency, and the radius of the exposed region is less than about 7.5×10 7 A/s to generate hysteresis heat in the diseased tissue.
Claim 2
Independent Claim
112 words
A method for site specific treatment of diseased tissue in a patient, comprising the steps of: (i) delivering a magnetic material which has a magnetic heating efficiency of at least about 4.5×10 -8 J.m./A.g. when magnetic field conditions are equal to or less than about 7.5×10 7 A/s to diseased tissue in a patient; and (ii) exposing the magnetic material in the patient to a linear alternating magnetic field with a frequency of greater than about 10 kHz and a field strength such that the product of field strength, frequency, and the radius of the exposed region is less than about 7.5×10 7 A/s to generate hysteresis heat in the diseased tissue.
Claim 3
Dependent Claim
26 words
The method of claim 1, wherein steps (i) to (ii) are repeated until the diseased tissue has at least been treated sufficiently to ameliorate the disease.
Claim 4
Dependent Claim
21 words
The method of claim 1, wherein the diseased tissue contains at least a cancerous growth or contains one or more tumours.
Claim 5
Dependent Claim
35 words
The method of claim 1, wherein the magnetic material has a magnetic heating efficiency of greater than about 7×10 -8 J.m./A.g., when magnetic field conditions are equal to or less than about 7.5×10 7 A/s.
Claim 6
Dependent Claim
35 words
The method of claim 1, wherein the magnetic material has a magnetic heating efficiency of greater than about 1×10 -7 J.m./A.g., when magnetic field conditions are equal to or less than about 7.5×10 7 A/s.
Claim 7
Dependent Claim
31 words
The method of claim 1, wherein the magnetic material comprises a ferromagnetic material which contains at least an element selected from the group consisting of iron, manganese, arsenic, antimony, and bismith.
Claim 8
Dependent Claim
65 words
The method of claim 1, wherein the magnetic material is selected from compounds within the group of CrO 2 , metallic iron, cobalt, nickel, gamma-ferric oxide, cobalt-treated gamma-ferric oxide, ferrites of the general formula MO.Fe 2 O3 where M is a bivalent metal, cobalt-treated ferrites, or magnetoplumbite-type oxides (M type) with the general formula MO.6Fe 2 O 3 where M is a large divalent ion.
Claim 9
Dependent Claim
20 words
The method of claim 7, wherein the magnetic material is a compound within the group of cobalt-treated gamma-ferric oxide compounds.
Claim 10
Dependent Claim
20 words
The method of claim 7, wherein the magnetic material is a compound within the group of un-modified gamma-ferric oxide compounds.
Claim 11
Dependent Claim
19 words
The method of claim 7, wherein the magnetic material is a compound within the group of chromium dioxide compounds.
Claim 12
Dependent Claim
22 words
The method of claim 1, wherein the magnetic material is mixed in a biocompatible liquid emulsion prior to delivery into a patient.
Claim 13
Dependent Claim
17 words
The method of claim 1, wherein the magnetic material is bound in a matrix to form microcapsules.
Claim 14
Dependent Claim
18 words
The method of claim 12, wherein the microcapsules range in size from about 10 to about 100 microns.
Claim 15
Dependent Claim
18 words
The method of claim 13, wherein the microcapsules range in size from about 20 to about 50 microns.
Claim 16
Dependent Claim
18 words
The method of claim 14, wherein the microcapsules range in size from about 30 to about 40 microns.
Claim 17
Dependent Claim
26 words
The method of claim 12, wherein the microcapsules are adapted to bind, absorb, or contain a cytotoxic material which is released upon heating of the microcapsule.
Claim 18
Dependent Claim
21 words
The method of claim 12, wherein an ionizing radiation is applied to the diseased tissue in conjunction with the magnetic field.
Claim 19
Dependent Claim
17 words
The method of claim 17, wherein the radiation is applied by microcapsules which contain a radioactive compound.
Claim 20
Dependent Claim
20 words
The method of claim 1, wherein said exposing produces a rate of tissue heating greater than 60 mW/cm 3 .
Claim 21
Dependent Claim
18 words
The method of claim 19, wherein the rate of tissue heating is greater than 80 mW/cm 3 .
Claim 22
Dependent Claim
18 words
The method of claim 19, wherein the rate of tissue heating is greater than 100 mW/cm 3 .
Claim 23
Dependent Claim
23 words
The method of claim 1, wherein the linear alternating magnetic field has an operational frequency of from about 10 kHz to 100 MHz.
Claim 24
Dependent Claim
23 words
The method of claim 1, wherein the linear alternating magnetic field has an operational frequency of from about 10 kHz to 500 kHz.
Claim 25
Dependent Claim
23 words
The method of claim 1, wherein the linear alternating magnetic field has an operational frequency of from about 10 kHz to 100 kHz.
Claim 26
Dependent Claim
16 words
The method of claim 1, wherein the magnetic field has an operational frequency of 20 kHz.
Claim 27
Dependent Claim
28 words
The method of claim 12, wherein the microspheres are of a suitable size to pass through a patient's vasculature network and become dispersed and embolized within diseased tissue.
Claim 28
Dependent Claim
18 words
The method of claim 12, wherein the microcapsules range in density from 1 to 5 g/cm 3 .
Claim 29
Dependent Claim
18 words
The method of claim 12, wherein the microcapsules range in density from 1.8 to 3 g/cm 3 .
Claim 30
Dependent Claim
18 words
The method of claim 12, wherein the microcapsules range in density from 1.8 to 2.2 g/cm 3 .
Claim 31
Dependent Claim
17 words
The method of claim 12, wherein the microcapsules have a density of about 2 g/cm 3 .
Claim 32
Dependent Claim
21 words
The method of claim 1, wherein the magnetic material is bound together using a copolymer of (R)-3-hydroxybutyric acid and (R)-3-hydroxyvaleric acid.
Claim 33
Dependent Claim
37 words
The method of claim 1, wherein the magnetic material is bound together using a copolymer of (R-3-hydroxybutyric acid and (R)-3-hydroxyvaleric acid, having a density range of 1.8-2.2 g/cm 3 and a range in size from 20-50 microns.
Claim 34
Dependent Claim
33 words
The method of claim 3, wherein the magnetic material is delivered to the diseased tissue by any one of the administration methods selected from the group consisting of intratumoral, peritumoral, or intravascular administrations.
Claim 35
Dependent Claim
21 words
The method of claim 1, wherein the magnetic material is delivered to the diseased tissue by arterial or venous blood supply.
Claim 36
Dependent Claim
23 words
The method of claim 1, wherein the magnetic material is delivered to the diseased tissue in combination with at least a vasoactive agent.
Claim 37
Independent Claim
97 words
A method for generating hysteresis heat in a tissue, comprising: delivering to the tissue magnetic material having a magnetic heating efficiency of at least about 4.5×10 -8 J.m./A.g., when the magnetic field conditions are about 7.5×10 7 A/s or less; and exposing the tissue, containing the delivered magnetic material, to a linear alternating magnetic field with a frequency of about 10 kHz or greater and a field strength such that the product of field strength, frequency, and the radius of the exposed tissue is less than about 7.5×10 7 A/s to generate hysteresis heat in the tissue.
Claim 38
Independent Claim
97 words
A method for generating hysteresis heat in a tissue, comprising: delivering to the tissue magnetic material having a magnetic heating efficiency of at least about 4.5×10 -8 J.m./A.g., when the magnetic field conditions are about 7.5×10 7 A/s or less; and exposing the tissue, containing the delivered magnetic material, to a linear alternating magnetic field with a frequency of about 10 kHz or greater and a field strength such that the product of field strength, frequency, and the radius of the exposed tissue is less than about 7.5×10 7 A/s to generate hysteresis heat in the tissue.
Claim 39
Dependent Claim
20 words
The method of claim 36, wherein the tissue contains at least a cancerous growth or contains one or more tumor.
Claim 40
Dependent Claim
22 words
The method of claim 37, wherein said delivery and exposure are repeated until said cancerous growth or tumor is reduced in size.
Claim 41
Independent Claim
104 words
A method for the treatment of cancerous growth or tumors, comprising: delivering to a tissue containing a cancerous growth or tumor, a magnetic material having a magnetic heating efficiency of at least about 4.5×10 -8 J.m./A.g., when the magnetic field conditions are about 7.5×10 7 A/s or less; and exposing the tissue, containing the delivered magnetic material, to a linear alternating magnetic field with a frequency of about 10 kHz or greater and a field strength such that the product of field strength, frequency, and the radius of the exposed tissue is less than about 7.5×10e7 A/s to generate hysteresis heat in the tissue.
Claim 42
Independent Claim
104 words
A method for the treatment of cancerous growth or tumors, comprising: delivering to a tissue containing a cancerous growth or tumor, a magnetic material having a magnetic heating efficiency of at least about 4.5×10 -8 J.m./A.g., when the magnetic field conditions are about 7.5×10 7 A/s or less; and exposing the tissue, containing the delivered magnetic material, to a linear alternating magnetic field with a frequency of about 10 kHz or greater and a field strength such that the product of field strength, frequency, and the radius of the exposed tissue is less than about 7.5×10e7 A/s to generate hysteresis heat in the tissue.
Claim 43
Independent Claim
100 words
A method for the heat treatment of a target tissue in a patient, comprising the steps of: administering to the patient's tissue magnetic material having a magnetic heating efficiency of at least about 4.5×10 -8 J.m./A.g., when the magnetic field conditions are about 7.5×10 7 A/s or less; and selectively exposing the tissue to a linear alternating magnetic field with a frequency of about 10 kHz or greater and a field strength such that the product of field strength, frequency, and the radius of the exposed tissue is less than about 7.5×10e7 A/s to generate hysteresis heat in the tissue.
Claim 44
Independent Claim
100 words
A method for the heat treatment of a target tissue in a patient, comprising the steps of: administering to the patient's tissue magnetic material having a magnetic heating efficiency of at least about 4.5×10 -8 J.m./A.g., when the magnetic field conditions are about 7.5×10 7 A/s or less; and selectively exposing the tissue to a linear alternating magnetic field with a frequency of about 10 kHz or greater and a field strength such that the product of field strength, frequency, and the radius of the exposed tissue is less than about 7.5×10e7 A/s to generate hysteresis heat in the tissue.
Claim 45
Dependent Claim
15 words
The method of claim 40, wherein said administering comprises injecting microcapsules comprising the magnetic material.
Claim 46
Dependent Claim
13 words
The method of claim 40, wherein said microcapsules further comprise a cytotoxic agent.
Claim 47
Dependent Claim
16 words
The method of claim 40, further comprising the step of: exposing the tissue to ionizing radiation.
Claim 48
Dependent Claim
14 words
The method of claim 43, wherein said exposure is from an external radiation source.
Claim 49
Dependent Claim
13 words
The method of claim 41, wherein said microcapsules further comprise a radioactive compound.
References Cited (Backward Citations)
US4303636A
Cited
US4106488A
Cited
US4323056A
Cited
US4574782A
Cited
US4545368A
Cited
US4662359A
Cited
US4983159A
Cited
EP0361797A1
Cited
WO1994012101A1
Cited
US5236410A
Cited
US5468210A
Cited
US5411730A
Cited
WO1995015786A1
Cited
US5429583A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-12-26 | 2004-06-26 | 2004-12-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-12-26 | 2008-06-26 | 2008-12-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-12-26 | 2012-06-26 | 2012-12-26 | $7700.00 | Window Closed / Lapsed |